These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

535 related articles for article (PubMed ID: 22759639)

  • 1. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability.
    Wang R; Burnett AL; Heller WH; Omori K; Kotera J; Kikkawa K; Yee S; Day WW; DiDonato K; Peterson CA
    J Sex Med; 2012 Aug; 9(8):2122-9. PubMed ID: 22759639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treating erectile dysfunction and central neurological diseases with oral phosphodiesterase type 5 inhibitors. Review of the literature.
    Lombardi G; Nelli F; Celso M; Mencarini M; Del Popolo G
    J Sex Med; 2012 Apr; 9(4):970-85. PubMed ID: 22304626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SOP conservative (medical and mechanical) treatment of erectile dysfunction.
    Porst H; Burnett A; Brock G; Ghanem H; Giuliano F; Glina S; Hellstrom W; Martin-Morales A; Salonia A; Sharlip I;
    J Sex Med; 2013 Jan; 10(1):130-71. PubMed ID: 23343170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis.
    Yuan J; Zhang R; Yang Z; Lee J; Liu Y; Tian J; Qin X; Ren Z; Ding H; Chen Q; Mao C; Tang J
    Eur Urol; 2013 May; 63(5):902-12. PubMed ID: 23395275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 10-Year analysis of adverse event reports to the Food and Drug Administration for phosphodiesterase type-5 inhibitors.
    Lowe G; Costabile RA
    J Sex Med; 2012 Jan; 9(1):265-70. PubMed ID: 22023666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Medicinal therapy of benign prostate syndrome with phosphodiesterase-5 inhibitors].
    Herlemann A; Gratzke C; Andersson KE; Sievert KD
    Urologe A; 2013 Feb; 52(2):204-11. PubMed ID: 23417046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A return to normal erectile function with tadalafil once daily after an incomplete response to as-needed PDE5 inhibitor therapy.
    Kim ED; Seftel AD; Goldfischer ER; Ni X; Burns PR
    J Sex Med; 2014 Mar; 11(3):820-30. PubMed ID: 23841532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia.
    Gacci M; Corona G; Salvi M; Vignozzi L; McVary KT; Kaplan SA; Roehrborn CG; Serni S; Mirone V; Carini M; Maggi M
    Eur Urol; 2012 May; 61(5):994-1003. PubMed ID: 22405510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphodiesterase inhibitors for erectile dysfunction in patients with diabetes mellitus.
    Vardi M; Nini A
    Cochrane Database Syst Rev; 2007 Jan; 2007(1):CD002187. PubMed ID: 17253475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review of phosphodiesterases in the urogenital system: new directions for therapeutic intervention.
    Montorsi F; Corbin J; Phillips S
    J Sex Med; 2004 Nov; 1(3):322-36. PubMed ID: 16422964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erectile dysfunction diagnosis and treatment as a means to improve medication adherence and optimize comorbidity management.
    Scranton RE; Goldstein I; Stecher VJ
    J Sex Med; 2013 Feb; 10(2):551-61. PubMed ID: 23153075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the first intake of vardenafil and tadalafil in patients with diabetic neuropathy and diabetic erectile dysfunction.
    Kamenov ZA
    J Sex Med; 2011 Mar; 8(3):851-64. PubMed ID: 21143421
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Avanafil, a potent and highly selective phosphodiesterase-5 inhibitor for erectile dysfunction.
    Kotera J; Mochida H; Inoue H; Noto T; Fujishige K; Sasaki T; Kobayashi T; Kojima K; Yee S; Yamada Y; Kikkawa K; Omori K
    J Urol; 2012 Aug; 188(2):668-74. PubMed ID: 22704456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adherence to initial PDE-5 inhibitor treatment: randomized open-label study comparing tadalafil once a day, tadalafil on demand, and sildenafil on demand in patients with erectile dysfunction.
    Buvat J; Büttner H; Hatzimouratidis K; Vendeira PA; Moncada I; Boehmer M; Henneges C; Boess FG
    J Sex Med; 2013 Jun; 10(6):1592-602. PubMed ID: 23551622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphodiesterase type 5 (PDE5) inhibitors in erectile dysfunction: the proper drug for the proper patient.
    Corona G; Mondaini N; Ungar A; Razzoli E; Rossi A; Fusco F
    J Sex Med; 2011 Dec; 8(12):3418-32. PubMed ID: 21995676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phosphodiesterase 5 inhibitors for erectile dysfunction.
    Setter SM; Iltz JL; Fincham JE; Campbell RK; Baker DE
    Ann Pharmacother; 2005; 39(7-8):1286-95. PubMed ID: 15941818
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of phosphodiesterase type 5 inhibitors for lower urinary tract symptoms.
    Miller MS
    Ann Pharmacother; 2013 Feb; 47(2):278-83. PubMed ID: 23386068
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical monograph for drug formulary review: erectile dysfunction agents.
    Campbell HE
    J Manag Care Pharm; 2005 Mar; 11(2):151-71. PubMed ID: 15766322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erectile dysfunction and the drugs to treat it. In many cases, medications are all a man needs to stay sexually active.
    Harv Health Lett; 2014 May; 39(7):7. PubMed ID: 25073193
    [No Abstract]   [Full Text] [Related]  

  • 20. 2009 update on phosphodiesterase type 5 inhibitor therapy part 2: updates on optimal utilization for sexual concerns and rare toxicities in this class.
    Shindel AW
    J Sex Med; 2009 Sep; 6(9):2352-64; quiz 2365-6. PubMed ID: 19735356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.